News

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...
Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
On today's Market Minute, Madison Mills takes a closer look at the top stories on Wall Street. UnitedHealth Group (UNH) stock ...